Predictive model of postoperative pneumonia after neoadjuvant immunochemotherapy for esophageal cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of gastrointestinal oncology"
DOI: 10.21037/jgo-22-149
Abstract: Background Postoperative pneumonia (PP) is the most common pulmonary complication of esophagectomy. It is of great importance to identify any high-risk factors and prevent pulmonary complications to improve the prognosis of patients with esophageal cancer… read more here.
Keywords: esophageal cancer; postoperative pneumonia; immunochemotherapy; neoadjuvant immunochemotherapy ... See more keywords
Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers
Sign Up to like & getrecommendations! Published in 2022 at "Translational Lung Cancer Research"
DOI: 10.21037/tlcr-22-439
Abstract: Background This retrospective study aimed to evaluate the real-world efficacy of neoadjuvant immunochemotherapy in locally advanced stage III non-small cell lung cancer (NSCLC), with a particular focus on analyzing the optimal treatment cycle and peripheral… read more here.
Keywords: locally advanced; lung cancer; immunochemotherapy locally; neoadjuvant immunochemotherapy ... See more keywords
A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Inflammation Research"
DOI: 10.2147/jir.s395231
Abstract: Purpose Neoadjuvant immunochemotherapy (nICT) for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) has attracted widespread attention recently, whose safety and clinical benefit was observed in clinical researches. This study aimed to develop and validate… read more here.
Keywords: escc patients; locally advanced; neoadjuvant immunochemotherapy; predictor ... See more keywords
Neoadjuvant immunochemotherapy in the treatment of nonmetastatic muscle-invasive bladder cancer: a systematic review.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2022-0039
Abstract: Introduction: Multiple trials are currently studying the additional effect of immunotherapy on neoadjuvant chemotherapy (NAC) in nonmetastatic muscle-invasive bladder cancer. Methods: We performed a systematic review of the literature that summarizes all ongoing trials, with… read more here.
Keywords: invasive bladder; neoadjuvant immunochemotherapy; bladder cancer; systematic review ... See more keywords
Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Bioengineering and Biotechnology"
DOI: 10.3389/fbioe.2022.1010672
Abstract: Introduction: Biomarkers predicting tumor response to neoadjuvant immunochemotherapy in non-small cell lung cancer (NSCLC) are still lacking despite great efforts. We aimed to assess the effectiveness of the immune PET Response Criteria in Solid Tumors… read more here.
Keywords: tumor response; ipercist max; neoadjuvant immunochemotherapy; response ... See more keywords
Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.984666
Abstract: This study evaluated the efficacy of neoadjuvant immunochemotherapy (Io+Chemo) versus chemotherapy alone (Chemo) in resectable non–small cell lung cancer (NSCLC) in a real-world setting. The association of tumor immune microenvironment (TIME) with pathologic response to… read more here.
Keywords: resectable non; cell; non small; neoadjuvant immunochemotherapy ... See more keywords
Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical–pathological outcomes in non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.909726
Abstract: Introduction The interval between neoadjuvant immunochemotherapy and surgery in patients with non-small cell lung cancer (NSCLC) has not been well characterized. This study investigated the association between the time-to-surgery (TTS) interval and surgical–pathological outcomes. Method… read more here.
Keywords: interval neoadjuvant; neoadjuvant immunochemotherapy; surgery; group ... See more keywords
Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1131883
Abstract: Background and purpose Unnecessary surgery can be avoided, and more appropriate treatment plans can be developed for patients if the efficacy of neoadjuvant immunochemotherapy for esophageal cancer (EC) can be predicted before surgery. The purpose… read more here.
Keywords: neoadjuvant immunochemotherapy; machine; machine learning; learning models ... See more keywords